What changed recently
Newly published and updated guidelines across every system, newest first. Each entry links to the official source.
13 older updates are outside this window. Show all time
- Gastrointestinal & HepatologyUS2026-07-012021 → 2026Diverticulitis
ACG replaced its 2021 diverticular disease guideline with a document focused on colonic diverticulitis, formalising selective rather than routine antibiotics for low-risk acute uncomplicated disease and listing the high-risk features (immunocompromise, frailty, unsafe outpatient care) that still warrant them. It also recommends against probiotics, mesalamine and rifaximin for recurrence prevention, drops nut/seed/popcorn avoidance, and limits post-recovery colonoscopy to complicated disease or patients with alarm features or overdue screening.
source ↗curation confidence 90% - Gastrointestinal & HepatologyUS2025-11-012018 → 2025 updateHepatitis B
The 2025 AASLD/IDSA guideline tackles six GRADE-based questions the 2018 guidance left unresolved, including whether to treat HBsAg-positive people in the immune-tolerant and indeterminate phases, when to withdraw antiviral therapy, and HCC surveillance in HBV coinfection and after HBsAg loss. Recommendations from 2018 that were not revisited remain in force, and an integrated algorithm combines old and new guidance.
source ↗curation confidence 90% - Gastrointestinal & HepatologyUS2025-06-012018 → 2025Crohn disease
The 2025 ACG guideline moves away from the 2018 step-up model, suggesting against requiring failure of conventional therapy before starting advanced therapy and endorsing early treat-to-target management with therapy chosen by phenotype and prior exposure. It also recommends combination infliximab plus a thiopurine over either agent alone in biologic- and immunomodulator-naive patients.
source ↗curation confidence 90% - Gastrointestinal & HepatologyUS2025-06-012019 → 2025 updateUlcerative colitis
This update revises the 2019 ACG ulcerative colitis guideline with five years of new trial evidence, expanding and repositioning advanced therapies for moderate-to-severe disease. Etrasimod, an S1P receptor modulator, is newly recommended for both induction and maintenance of remission.
source ↗curation confidence 90% - Gastrointestinal & HepatologyEU2025-05-102017 → 2025Hepatitis B
EASL's 2025 hepatitis B guideline shifts from indefinite viral suppression toward personalised, finite therapy with functional cure (sustained HBsAg loss) as the goal. Newer biomarkers including quantitative HBsAg, HBcrAg and HBV RNA are built into disease staging, treatment selection and decisions about safely stopping antivirals.
source ↗curation confidence 90% - Gastrointestinal & HepatologyEU2024-10-012020 → 2024Crohn disease
The 2024 ECCO therapeutics update adds strong recommendations for the newer agents risankizumab (maintenance) and upadacitinib (induction and maintenance) in moderate-to-severe Crohn's disease, broadening options beyond anti-TNF and older biologics. It also restructures the guidance into actionable practice points alongside the GRADE recommendations carried over from 2020.
source ↗curation confidence 90%